FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095380018> ?p ?o ?g. }

• W2095380018 endingPage "205" @default.
• W2095380018 startingPage "205" @default.
• W2095380018 abstract "TO THE EDITOR: Acquired hemophilia A (AHA) is a very rare condition with an incidence of about 1.5 per million of the general population per year [1]. It develops in middle age due to autoantibody production directly against the factor VIII (FVIII) and occurs in both sexes equally. The underlying conditions associated with AHA are other autoimmune diseases, malignancy, drugs and pregnancy. However, about half of AHA has no specific cause, thus they are called idiopathic. Postpartum AHA is a special category with distinct clinical manifestation contributing to 7-21% of patients with AHA [2, 3, 4]. In Korea, the first case of postpartum AHA in a 40 years old female has been reported by Lee et al. [5]. To the best of our knowledge, the present case report is the second one in Korea.A previously healthy 18 years old female had several minor bruises on hands and feet at 5 months after delivery. There was no specific complication immediately after delivery. She previously didn't take any drugs which could result in AHA and her family history was nonspecific. The hemorrhagic symptoms were aggravated during the process of time and she visited a private medical doctor at 8 months after delivery. At the medical clinic, she was only supplemented with iron to treat her iron deficiency anemia. Because of a persistent migrating painful swelling on her knees and ankle joints, multiple bruises and menorrhagia, she was transferred to our institute at 9 months after delivery.Her initial laboratory test results were as follows: PT 10.2 sec (normal range, 10-14 sec), INR 0.95 (normal range, 0.85-1.50), aPTT 84.3 sec (normal range, 20-40 sec), FVIII activity 1.4% (moderately decreased), and anti-FVIII antibody 28 Bedestha units (BU). Thus, she was confirmed as postpartum AHA. To manage her persisting hemorrhagic symptoms, activated prothrombin complex concentrate, FEIBA (Baxter, Westlake Village, CA, USA) was infused to her based on the dose for joint hemorrhage (50-100 units/kg every 12 hours until pain/disabilities are improved, maximum 200 units/kg/day) and her bleeding symptoms resolved. We closely followed up her at the outpatient clinic with on-demand FEIBA injection. After 2 months, the last follow up PT/aPTT were 11.2/95.1 sec, FVIII activity 1.5% and anti-FVIII antibody 40 BU. We consider giving corticosteroid to her additionally.According to European Acquired Haemophilia (EACH2) registry, 42 cases of postpartum AHA developed from 2003 to 2008 in 13 European countries [4]. In other words, the medical personnel in hematology or obstetrics can experience one postpartum AHA patient every year or biyearly in one country. Because time to diagnosis of postpartum AHA was 21-120 days after delivery, pregnant women should be observed closely approximately 1-3 months after delivery [4].Usually, AHA is often misunderstood as another bleeding disorder like disseminated intravascular coagulation because a hemorrhage into the skin (purpura) or soft tissue is the most common presenting sign of AHA, while a hemarthrosis, the hole mark of a congenital hemophilia, occurs rarely [1, 2]. According to EACH2, hemarthrosis was also a rare hemorrhagic symptom of postpartum AHA contributing about 5%. Subcutaneous (45%) or mucosal bleeding (43%) was most common. On the other hand, in case of our report, the patient was mistaken as to have rheumatic disease because the migrating painful swelling of her joints due to hemarthrosis was the main symptom.The treatment of acute bleeding in case of postpartum AHA is not different from the general form. Two bypassing agents, FEIBA and the recombinant activated factor VII, NovoSeven (Novo Nordisk, Princeton, NJ, USA) are the main therapeutic agents to control acute hemorrhagic symptoms. The overall complete response rate of hemorrhages using FEIBA was 86% with the infusion of 75 units/kg every 8 to 12 hours [6]. And the efficacy rate using NovoSeven was 95% as first line therapy for AHA [7]. NovoSeven has some advantages that it's blood born viral transmission is shut out and the risk of thromboembolism is lower than that of FEIBA [8, 9].The combination of bypassing agents for stopping the hemorrhage and immunosuppressive therapy is usually used together to eradicate the autoantibodies of FVIII in the general form of AHA. Prednisolone (prednisone), cyclophosphamide, azathioprine, 6-mercaptopurine, rituximab (anti-CD 20 monoclonal antibody), mycophenolate or cyclosporin have been used for treatment [1, 3, 10, 11, 12].However, the immunosuppression may be individually reserved considering the advantages and disadvantages in case of postpartum AHA because of its more favorable prognosis compared to the general form. In retrospective reviews of postpartum AHAs, 86-100% of patients showed complete remission and survival rate was 97-100% [4, 12]. Further, there was no statistical difference of the time to complete remission between the postpartum AHA patients had immunosuppressive therapy and the rest of cohort [4]. On the other hand, the course of a general AHA is quite different. The relapse rate was about 20% after the cessation of immunosuppression and the survival rate was about 60% [1].In some international survey, the recurrence rate of postpartum AHA was 0% [13, 14]. However, there is a controversy over the recurrence rate of anti-FVIII antibody in case of subsequent pregnancy. Large-scaled study about the recurrence rate is not available yet. Thus the patients who experienced postpartum AHA should be observed carefully after subsequent pregnancies.In the previous Korean case of postpartum AHA reported by Lee et al. [5], the patient was treated with a bypassing agent plus corticosteroid. In the present case, we are using on-demand FEIBA infusion for control of acute bleeding and postponed the immunosuppression considering a spontaneous remission. In our present case, the hemorrhagic symptoms of the patient were now solved using FEIBA. We expect that case presentations will help to increase the awareness on this rare condition among the medical personnel in the hematologic and obstetric field." @default.
• W2095380018 created "2016-06-24" @default.
• W2095380018 creator A5039335852 @default.
• W2095380018 creator A5039679442 @default.
• W2095380018 creator A5055474084 @default.
• W2095380018 creator A5063838307 @default.
• W2095380018 date "2014-01-01" @default.
• W2095380018 modified "2023-10-01" @default.
• W2095380018 title "Second case of postpartum acquired hemophilia A in a Korean female" @default.
• W2095380018 cites W100012739 @default.
• W2095380018 cites W1480061065 @default.
• W2095380018 cites W1522420709 @default.
• W2095380018 cites W15759395 @default.
• W2095380018 cites W1605230984 @default.
• W2095380018 cites W1889532155 @default.
• W2095380018 cites W1966116086 @default.
• W2095380018 cites W1973815363 @default.
• W2095380018 cites W1996499278 @default.
• W2095380018 cites W2039064237 @default.
• W2095380018 cites W2039943613 @default.
• W2095380018 cites W2063653871 @default.
• W2095380018 cites W2065744369 @default.
• W2095380018 cites W2079969115 @default.
• W2095380018 cites W2106722871 @default.
• W2095380018 cites W2130223637 @default.
• W2095380018 cites W2133489484 @default.
• W2095380018 cites W2155989382 @default.
• W2095380018 cites W2157045826 @default.
• W2095380018 cites W2160573171 @default.
• W2095380018 cites W2266032904 @default.
• W2095380018 doi "https://doi.org/10.5045/br.2014.49.3.205" @default.
• W2095380018 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4188791" @default.
• W2095380018 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25325045" @default.
• W2095380018 hasPublicationYear "2014" @default.
• W2095380018 type Work @default.
• W2095380018 sameAs 2095380018 @default.
• W2095380018 citedByCount "2" @default.
• W2095380018 countsByYear W20953800182019 @default.
• W2095380018 countsByYear W20953800182021 @default.
• W2095380018 crossrefType "journal-article" @default.
• W2095380018 hasAuthorship W2095380018A5039335852 @default.
• W2095380018 hasAuthorship W2095380018A5039679442 @default.
• W2095380018 hasAuthorship W2095380018A5055474084 @default.
• W2095380018 hasAuthorship W2095380018A5063838307 @default.
• W2095380018 hasBestOaLocation W20953800181 @default.
• W2095380018 hasConcept C131872663 @default.
• W2095380018 hasConcept C187212893 @default.
• W2095380018 hasConcept C29456083 @default.
• W2095380018 hasConcept C71924100 @default.
• W2095380018 hasConceptScore W2095380018C131872663 @default.
• W2095380018 hasConceptScore W2095380018C187212893 @default.
• W2095380018 hasConceptScore W2095380018C29456083 @default.
• W2095380018 hasConceptScore W2095380018C71924100 @default.
• W2095380018 hasIssue "3" @default.
• W2095380018 hasLocation W20953800181 @default.
• W2095380018 hasLocation W20953800182 @default.
• W2095380018 hasLocation W20953800183 @default.
• W2095380018 hasLocation W20953800184 @default.
• W2095380018 hasOpenAccess W2095380018 @default.
• W2095380018 hasPrimaryLocation W20953800181 @default.
• W2095380018 hasRelatedWork W1999344589 @default.
• W2095380018 hasRelatedWork W2391778245 @default.
• W2095380018 hasRelatedWork W2409957712 @default.
• W2095380018 hasRelatedWork W2410491650 @default.
• W2095380018 hasRelatedWork W2604682584 @default.
• W2095380018 hasRelatedWork W2748952813 @default.
• W2095380018 hasRelatedWork W2783428915 @default.
• W2095380018 hasRelatedWork W2789448498 @default.
• W2095380018 hasRelatedWork W2899084033 @default.
• W2095380018 hasRelatedWork W4250651714 @default.
• W2095380018 hasVolume "49" @default.
• W2095380018 isParatext "false" @default.
• W2095380018 isRetracted "false" @default.
• W2095380018 magId "2095380018" @default.
• W2095380018 workType "article" @default.